Quanterix 2025 Q3 Earnings Net Loss Widens 301.3% to $33.52M

Quanterix (QTRX) reported its fiscal 2025 Q3 earnings on Nov 11, 2025, with a 12.3% revenue increase to $40.23 million, exceeding the $38.18 million forecast. However, the EPS of -$0.73 missed expectations of -$0.53. The company maintained its 2025 revenue guidance of $130–$135 million, emphasizing cash flow breakeven by 2026.

Revenue

Product revenue led the way at $26.15 million, while service and other revenue totaled $13.95 million. Collaboration and license revenue contributed $46,000, and grant revenue added $83,000, culminating in total revenue of $40.23 million. The 12.3% year-over-year increase reflects strong demand for Quanterix’s products and services.

Earnings/Net Income

Quanterix’s losses deepened to $0.73 per share, a 231.8% wider loss, with a net loss of $33.52 million, representing a 301.3% increase from $8.35 million in 2024 Q3. The EPS shortfall and significantly expanded net loss indicate a challenging financial period for the company.

Post-Earnings Price Action Review

The strategy of buying QTRX when revenue beats and holding for 30 days shows promising potential. Quanterix’s $40.2 million revenue beat, coupled with a 3.64% post-earnings stock surge, signals market optimism. The company’s focus on Alzheimer’s diagnostics, R&D investments, and Akoya integration synergies position it for long-term growth. Anticipated cash flow breakeven in 2026 and strategic partnerships further bolster investor confidence. However, monitoring EPS performance and integration progress is critical to sustaining this strategy.

CEO Commentary

CEO Masoud Toloue highlighted the company’s revenue delivery amid challenges, noting $85 million in annualized synergies from the Akoya acquisition. He emphasized Alzheimer’s diagnostics momentum, driven by Medicare pricing and Asia-Pacific partnerships, and expressed optimism about 2026 cash flow breakeven.

Guidance

Quanterix reiterated 2025 revenue guidance of $130–$135 million, with pro forma revenue of $165–$170 million. The company expects GAAP/adjusted gross margins of 45–47%, adjusted cash usage of $34–$38 million, and exiting 2025 with ~$120 million in cash.

Additional News

Quanterix advanced its strategic integration of Akoya, realizing $67 million of $85 million in synergies. CEO Masoud Toloue and CFO Vandana Sriram underscored progress in Alzheimer’s diagnostics, including a positive Medicare pricing recommendation and Asia-Pacific partnerships. R&D investments, particularly in Simoa One and Alzheimer’s assays, remain a priority. The company also outlined plans for a cash flow breakeven in 2026, driven by cost synergies and operational efficiencies.

Conclusion

Quanterix’s Q3 2025 results highlight resilience in revenue growth despite a widening net loss. Strategic integration, Alzheimer’s diagnostics expansion, and cash flow targets position the company for future recovery. Investors should monitor execution on synergies and market adoption of key innovations.